The ESGCT Board is composed of researchers and clinicians representing a broad range of European Countries. Board members are elected by nomination and vote at the Annual General Meeting which is usually held during the Annual Congress.
The President and Vice-President of the society are appointed for two years and the other members of the Board are appointed for three years. For full details of governance arrangements please see our constitution.
División de Terapias Innovadoras en el Sistema Hematopoyético CIEMAT Av. Complutense, 40 28040 Madrid
Telethon Institute Of Genetics And Medicine Via Pietro Castellino, 111 80131 Naples
Hannover Medical School Institute of Experimental Hematology OE6960 Hannover Medical School Carl Neuberg Str. 1 Hannover 30625
FIMA, Av Pio XII 55 Pamplona 31008
UCL Institute of Child Health 30 Guilford St London WC1N 1EH
Drug Research Program Faculty of Pharmacy University of Helsinki Biocenter 2 Viikinkaari 5E, 00790 Helsinki
San Raffaele Telethon Institute for Gene Therapy Via Olgettina 60 Milano 20132
ART-TG – Inserm US35 30 rue H. Desbruères 91100 Corbeil-Essonnes
VIR, INSERM U758 Ecole normal supérieure de Lyon, Université de Nice
If you would like to express an interest in becoming a Board member please don’t hesitate to contact office@esgct.eu for details of the nomination process; ESGCT members will automatically be emailed when positions become available. Click here to view the board election process.
The ESGCT offers up to 3 spaces on the ESGCT Board for co-opted student and early career researcher (ECR) members with special responsibilities for young investigators. You can read about it here.
Private Board area
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!